Efficacy and safety of riociguat in early pulmonary vascular disease (ESRA): a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIa trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of riociguat in early pulmonary vascular disease (ESRA): a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIa trial.
Authors: Xanthouli P; Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital and Translational Lung Research Centre Heidelberg (TLRC), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany; Department of Internal Medicine V: Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Benjamin N; Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital and Translational Lung Research Centre Heidelberg (TLRC), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany., Coghlan G; Department of Cardiology, Royal Free London NHS Foundation Trust, London, United Kingdom., Denton CP; Centre for Rheumatology, Division of Medicine, Royal Free Campus, University College London, London, United Kingdom., Douschan P; Division of Respiratory Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria., Hachulla É; Department of Internal Medicine and Clinical immunology, Referral Centre for Rare Systemic Auto-immune and auto-inflammatory Diseases North North-West Mediterranean and Guadeloupe (CeRAINOM), Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE, University of Lille, Lille, France., Halank M; Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus of Technical University Dresden, Dresden, Germany., Heberling M; Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus of Technical University Dresden, Dresden, Germany., Kovacs G; Division of Respiratory Medicine, Lung Research Cluster, Medical University of Graz, Graz, Austria., Lichtblau M; Department of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Marra AM; Department of Translational Medical Sciences, 'Federico II' University of Naples, 'Federico II' University Hospital and School of Medicine, Naples, Italy., Steringer-Mascherbauer R; Division of Cardiology, Angiology and Intensive Care, Department of Internal Medicine II, Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria., Ulrich S; Department of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Grünig E; Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital and Translational Lung Research Centre Heidelberg (TLRC), Member of the German Centre for Lung Research (DZL), Heidelberg, Germany. Electronic address: ekkehard.gruenig@med.uni-heidelberg.de.
Corporate Authors: ESRA investigators
Source: Chest [Chest] 2026 Jul 15. Date of Electronic Publication: 2026 Jul 15.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 0231335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1931-3543 (Electronic) Linking ISSN: 00123692 NLM ISO Abbreviation: Chest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1931-3543
DOI:10.1016/j.chest.2026.06.053